Objective: To evaluate the association between interleukin-12 (IL-12) gene polymorphism and cervical cancer susceptibility.
Methods: We comprehensively retrieved the relevant English and Chinese database to collect case-control studies on the association between the IL-12 gene polymorphism and cervical cancer susceptibility. Data were extracted independently by two researchers respectively, the summary data were analyzed using Revman 5.2 software, the association was described using odds ratios (OR) and 95% confidence intervals (95% CI).
Results: According to inclusion and exclusion criteria, 5 case-control studies involving 2552 cervical cancer patients and 2232 healthy controls were included. The meta-analysis results showed that 3'UTR+1188 (rs3212227) polymorphism in IL-12 gene was not associated with cervical cancer risk (C vs. A: OR=1.09, 95% CI: 0.88~1.35, P=0.45; AA+AC vs. CC: OR=0.88, 95% CI: 0.67~1.15, P=0.34; AA vs. AC+CC: OR=0.89. 95% CI: 0.56-1.42, P=0.62; CC vs. AA: OR=1.30. 95% CI: 0.79-2.12, P=0.30).
Conclusion: The available evidence suggested that rs3212227 polymorphism in IL-12 gene may not be the risk factor to cervical cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4483960 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Delineation of reduced CTV2 on the basis of the characteristics and distribution of cervical lymph node metastasis in nasopharyngeal carcinoma.
BMC Cancer
January 2025
Department of Radiation Oncology, First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, 650032, P. R. China.
Introduction: The core objective of this study was to precisely locate metastatic lymph nodes, identify potential areas in nasopharyngeal carcinoma patients that may not require radiotherapy, and propose a hypothesis for reduced target volume radiotherapy on the basis of these findings. Ultimately, we reassessed the differences in dosimetry of organs at risk (OARs) between reduced target volume (reduced CTV2) radiotherapy and standard radiotherapy.
Methods And Materials: A total of 209 patients participated in the study.
Reverse-engineering the FLT3-PI3K/AKT axis to enhance TILs function and improve prognosis in ovarian and cervical cancers.
J Ovarian Res
January 2025
Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, #128 Shenyang Road, Shanghai, 200090, People's Republic of China.
Background: Ovarian cancers (OC) and cervical cancers (CC) have poor survival rates. Tumor-infiltrating lymphocytes (TILs) play a pivotal role in prognosis, but shared immune mechanisms remain elusive.
Methods: We integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) to explore immune regulation in OC and CC, focusing on the PI3K/AKT pathway and FLT3 as key modulators.
An automatic cervical cell classification model based on improved DenseNet121.
Sci Rep
January 2025
Department of Biomedical Engineering, School of Life Science and Technology, Changchun University of Science and Technology, Changchun, 130022, China.
The cervical cell classification technique can determine the degree of cellular abnormality and pathological condition, which can help doctors to detect the risk of cervical cancer at an early stage and improve the cure and survival rates of cervical cancer patients. Addressing the issue of low accuracy in cervical cell classification, a deep convolutional neural network A2SDNet121 is proposed. A2SDNet121 takes DenseNet121 as the backbone network.
View Article and Find Full Text PDFHow can cervical screening meet the needs of vulnerable women? A qualitative comparative study with stakeholder perspectives from seven European countries.
BMJ Open
January 2025
University Research Clinic for Cancer Screening, Randers Regional Hospital, Randers, Denmark.
Objective: This study explored and compared stakeholder perspectives on enhancements to cervical cancer screening for vulnerable women across seven European countries.
Design: In a series of Collaborative User Boards, stakeholders were invited to collaborate on identifying facilitators to improve cervical cancer screening.
Setting: This study was part of the CBIG-SCREEN project which is funded by the European Union and targets disparities in cervical cancer screening for vulnerable women (www.
Racial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies.
Am J Obstet Gynecol
January 2025
Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Background: Black women and other minorities have higher age adjusted incidence risk for cervical and endometrial cancer than White women. However, the extent of racial and ethnic disparities in clinical trial enrollment among studies performed mainly in North America and Europe for gynecologic malignancy is unknown.
Objective: This study analyzed enrollment rates by race/ethnicity in trials that led to Food and Drug Administration (FDA) approvals for gynecological cancers from 2010 to 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!